Developer docs
API playgroundTry for free, no card

Search company profiles

Edesa Biotech

Full company profile

uuid00058ml

Namestring
Edesa Biotech
Legal namestring
Edesa Biotech Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Edesa Biotech is a clinical-stage biopharmaceutical company founded in 2015 by Dr. Par Nijhawan and headquartered in Markham, Ontario, Canada. The company went public in June 2019 via a reverse merger with Stellar Biotechnologies and trades on Nasdaq under the ticker EDSA. Edesa is incorporated under the laws of British Columbia and operates through a principal R&D subsidiary (Edesa Biotech Research) and a U.S. subsidiary in Southern California.

The company develops a portfolio of host-directed therapeutics—primarily monoclonal antibodies and enzyme inhibitors—targeting immune dysregulation pathways implicated in dermatological, respiratory, and inflammatory diseases. Its core pipeline consists of three drug candidates: paridiprubart (EB05), a first-in-class anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS) with additional development in acute kidney injury, sepsis, and pneumonia; EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01 (1.0% daniluromer cream), a Phase 3-ready topical sPLA2 inhibitor for allergic contact dermatitis. Paridiprubart demonstrated a 27% relative reduction in 28-day mortality across 278 randomized ARDS patients in a Phase 3 study, and the candidate has been selected by U.S. BARDA for a government-funded Phase 2 platform study.

Edesa is pre-revenue with no commercialized products, generating no product sales as of fiscal 2025. The company funds operations through periodic private placements (approximately $28.5 million raised across 2022-2026 PIPEs) and Canadian government grants (cumulative C$37 million from the Strategic Innovation Fund). Its customer base is essentially limited to capital providers, with a near-term revenue model dependent on eventual regulatory approval and pharmaceutical distribution through wholesalers, specialty pharmacies, and hospital purchasing systems, potentially in partnership with strategic collaborators for late-stage commercialization.

Short descriptiontext

Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed monoclonal antibody and topical therapeutics for acute respiratory distress syndrome, vitiligo, and allergic contact dermatitis. Pre-revenue and Nasdaq-listed under EDSA, the company serves patients with high-unmet-need inflammatory and immune-related diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarkham, Canada
HQ citystring
Markham
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
host-directed therapeutics, monoclonal antibody development, inflammatory disease treatment, clinical-stage biopharmaceuticals, dermatology therapeutics
Industry2 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical-stage Biopharmaceuticals / Host-Directed Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company. Once drug candidates receive regulatory approval, the company plans to commercialize products through traditional pharmaceutical distribution channels. Current products in development include paridiprubart for ARDS, EB06 for vitiligo, and EB01 for allergic contact dermatitis.

edesabiotech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Edesa Biotech is a clinical-stage biopharmaceutical company developing first-in-class host-directed therapeutics—monoclonal antibodies and topical enzyme inhibitors—for inflammatory and immune-related diseases. The company is advancing three drug candidates: paridiprubart (EB05), an anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS); EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01, a topical sPLA2 inhibitor cream for allergic contact dermatitis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 27% relative reduction in 28-day mortality (24% vs 33% placebo, p<0.001) across 278 randomized ARDS patients
+4 more records
Product overview1 text field

Edesa Biotech is a clinical-stage biopharmaceutical company developing a portfolio of monoclonal antibody and topical anti-inflammatory drug candidates for immuno-inflammatory diseases. The core pipeline consists of: Paridiprubart (EB05), a first-in-class anti-TLR4 antibody for respiratory conditions including ARDS and acute kidney injury; EB06, an anti-CXCL10 antibody for vitiligo; and EB01 (daniluromer cream), a Phase 3-ready sPLA2 inhibitor for allergic contact dermatitis. These candidates are developed through the company's Host Directed Therapeutics platform, which focuses on modulating the body's own immune response rather than directly targeting pathogens.

Product and service3 records
1Paridiprubart (EB05)
CategoryClinical-stage Biologic Drug Candidate
Description

A first-in-class anti-TLR4 monoclonal antibody being developed as a Host-Directed Therapeutic for Acute Respiratory Distress Syndrome (ARDS) and acute kidney injury (AKI). The drug modulates the body's immune response to treat respiratory conditions, with additional development for sepsis and pneumonia. Demonstrated 27% relative reduction in 28-day mortality across 278 Phase 3 patients (24% vs 33% placebo, p<0.001).

2EB06
CategoryClinical-stage Biologic Drug Candidate
Description

An anti-CXCL10 monoclonal antibody in development for moderate-to-severe non-segmental vitiligo, a common autoimmune disorder causing skin depigmentation. The drug targets the CXCL10 chemokine which plays a key role in the disease pathophysiology, with neutralization of CXCL10 demonstrated to both prevent and reverse depigmentation in animal models.

3EB01 (1.0% Daniluromer Cream)
CategoryClinical-stage Topical Drug Candidate
Description

A Phase 3-ready topical secretory phospholipase 2 (sPLA2) inhibitor cream being developed for allergic contact dermatitis, a common occupational skin condition. The drug targets sPLA2 at the inception of inflammation to provide anti-inflammatory effects without steroid-related safety concerns, addressing a common occupational health condition with limited non-steroidal treatment options.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-03-26
Description

JSS Medical Research serves as the contract research organization (CRO) for Edesa's clinical trials, including the Phase 2 vitiligo study for EB06 and Phase 3 studies for paridiprubart. The CRO conducted data analyses and manages international clinical trial operations.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma developing interferon beta-1a (trafermin) for ARDS; directly comparable to Edesa as a small-cap, clinical-stage host-directed therapeutic developer in the same ARDS indication.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics for inflammatory and dermatological diseases; comparable small-cap clinical pipeline model with dermatology/inflammation overlap.

TypeDirect peer
Description

Late-stage cell therapy company developing remestemcel-L for ARDS and inflammatory conditions; directly comparable in pursuing novel immune-modulating approaches to ARDS.

4Pluristem Therapeutics
TypeEmerging player
Description

Clinical-stage cell therapy company developing PLX cells for inflammatory and pulmonary conditions including ARDS; overlapping host-directed therapeutic strategy.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing immunomodulatory therapeutics; comparable small-cap clinical pipeline model focused on immune-related diseases.

TypeDirect peer
Description

Specialty biopharmaceutical company developing therapeutics for gastrointestinal and inflammatory diseases; similar clinical-to-commercial-stage profile and immunology focus.

TypeBroad incumbent
Description

Established biopharmaceutical company with Opzelura (ruxolitinib cream), an approved treatment for vitiligo; directly competitive in EB06's target indication and a benchmark for vitiligo commercial opportunity.

8Athersys
TypeEmerging player
Description

Clinical-stage cell therapy company that advanced MultiStem for ARDS; directly comparable in pursuing novel modalities for respiratory inflammation, though now restructured.

TypeBroad incumbent
Description

Large pharmaceutical company with established immunology and dermatology franchises (e.g., JAK inhibitor programs for vitiligo); broad incumbent with overlapping indications and far greater commercial reach.

TypeEmerging player
Description

Clinical-stage biotechnology company developing novel therapies; comparable small-cap clinical-stage biotech with platform-based therapeutic approach, though focused on different therapeutic area.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Edesa Biotech

Clinical-stage Biopharmaceuticals / Host-Directed Therapeuticsedesabiotech.com

Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed monoclonal antibody and topical therapeutics for acute respiratory distress syndrome, vitiligo, and allergic contact dermatitis. Pre-revenue and Nasdaq-listed under EDSA, the company serves patients with high-unmet-need inflammatory and immune-related diseases.

What Edesa Biotech does

Edesa Biotech is a clinical-stage biopharmaceutical company founded in 2015 by Dr. Par Nijhawan and headquartered in Markham, Ontario, Canada. The company went public in June 2019 via a reverse merger with Stellar Biotechnologies and trades on Nasdaq under the ticker EDSA. Edesa is incorporated under the laws of British Columbia and operates through a principal R&D subsidiary (Edesa Biotech Research) and a U.S. subsidiary in Southern California.

The company develops a portfolio of host-directed therapeutics—primarily monoclonal antibodies and enzyme inhibitors—targeting immune dysregulation pathways implicated in dermatological, respiratory, and inflammatory diseases. Its core pipeline consists of three drug candidates: paridiprubart (EB05), a first-in-class anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS) with additional development in acute kidney injury, sepsis, and pneumonia; EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01 (1.0% daniluromer cream), a Phase 3-ready topical sPLA2 inhibitor for allergic contact dermatitis. Paridiprubart demonstrated a 27% relative reduction in 28-day mortality across 278 randomized ARDS patients in a Phase 3 study, and the candidate has been selected by U.S. BARDA for a government-funded Phase 2 platform study.

Edesa is pre-revenue with no commercialized products, generating no product sales as of fiscal 2025. The company funds operations through periodic private placements (approximately $28.5 million raised across 2022-2026 PIPEs) and Canadian government grants (cumulative C$37 million from the Strategic Innovation Fund). Its customer base is essentially limited to capital providers, with a near-term revenue model dependent on eventual regulatory approval and pharmaceutical distribution through wholesalers, specialty pharmacies, and hospital purchasing systems, potentially in partnership with strategic collaborators for late-stage commercialization.

Edesa Biotech firmographics

Firmographics
Name
Edesa Biotech
Legal name
Edesa Biotech Inc.
Website
https://edesabiotech.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed monoclonal antibody and topical therapeutics for acute respiratory distress syndrome, vitiligo, and allergic contact dermatitis. Pre-revenue and Nasdaq-listed under EDSA, the company serves patients with high-unmet-need inflammatory and immune-related diseases.
Ownership category
akta.pro rank

Edesa Biotech industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals / Host-Directed Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Host-directed therapeutics
  • Monoclonal antibody development
  • Inflammatory disease treatment
  • Clinical-stage biopharmaceuticals
  • Dermatology therapeutics

Where Edesa Biotech is headquartered

Location

Headquarters

HQ city
Markham
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Edesa Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Once drug candidates receive regulatory approval, the company plans to commercialize products through traditional pharmaceutical distribution channels. Current products in development include paridiprubart for ARDS, EB06 for vitiligo, and EB01 for allergic contact dermatitis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Edesa Biotech product offering

Product offering

Core offering

Edesa Biotech is a clinical-stage biopharmaceutical company developing first-in-class host-directed therapeutics—monoclonal antibodies and topical enzyme inhibitors—for inflammatory and immune-related diseases. The company is advancing three drug candidates: paridiprubart (EB05), an anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS); EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01, a topical sPLA2 inhibitor cream for allergic contact dermatitis.

Product overview

Edesa Biotech is a clinical-stage biopharmaceutical company developing a portfolio of monoclonal antibody and topical anti-inflammatory drug candidates for immuno-inflammatory diseases. The core pipeline consists of: Paridiprubart (EB05), a first-in-class anti-TLR4 antibody for respiratory conditions including ARDS and acute kidney injury; EB06, an anti-CXCL10 antibody for vitiligo; and EB01 (daniluromer cream), a Phase 3-ready sPLA2 inhibitor for allergic contact dermatitis. These candidates are developed through the company's Host Directed Therapeutics platform, which focuses on modulating the body's own immune response rather than directly targeting pathogens.

Differentiator

Problem solved

Functional benefit

Products and services

  • Paridiprubart (EB05) A first-in-class anti-TLR4 monoclonal antibody being developed as a Host-Directed Therapeutic for Acute Respiratory Distress Syndrome (ARDS) and acute kidney injury (AKI). The drug modulates the body's immune response to treat respiratory conditions, with additional development for sepsis and pneumonia. Demonstrated 27% relative reduction in 28-day mortality across 278 Phase 3 patients (24% vs 33% placebo, p<0.001).
  • EB06 An anti-CXCL10 monoclonal antibody in development for moderate-to-severe non-segmental vitiligo, a common autoimmune disorder causing skin depigmentation. The drug targets the CXCL10 chemokine which plays a key role in the disease pathophysiology, with neutralization of CXCL10 demonstrated to both prevent and reverse depigmentation in animal models.
  • EB01 (1.0% Daniluromer Cream) A Phase 3-ready topical secretory phospholipase 2 (sPLA2) inhibitor cream being developed for allergic contact dermatitis, a common occupational skin condition. The drug targets sPLA2 at the inception of inflammation to provide anti-inflammatory effects without steroid-related safety concerns, addressing a common occupational health condition with limited non-steroidal treatment options.

Quantifiable outcome

  • 27% relative reduction in 28-day mortality (24% vs 33% placebo, p<0.001) across 278 randomized ARDS patients
  • +4 more outcomes

Companies that use Edesa Biotech

Customer profile

Segments4 records

Ideal customer profiles3 records

Edesa Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Edesa Biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • JSS Medical ResearchcoreImplementation/ SI/ Consulting Partner · 26 March 2026JSS Medical Research serves as the contract research organization (CRO) for Edesa's clinical trials, including the Phase 2 vitiligo study for EB06 and Phase 3 studies for paridiprubart. The CRO conducted data analyses and manages international clinical trial operations.

Scale indicators16 records

Recent moves7 records

Expansion highlights4 records

Edesa Biotech competitors and assessment

Company assessment

Direct peers

  • Faron Pharmaceuticals: Clinical-stage biopharma developing interferon beta-1a (trafermin) for ARDS; directly comparable to Edesa as a small-cap, clinical-stage host-directed therapeutic developer in the same ARDS indication.
  • InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics for inflammatory and dermatological diseases; comparable small-cap clinical pipeline model with dermatology/inflammation overlap.
  • Mesoblast: Late-stage cell therapy company developing remestemcel-L for ARDS and inflammatory conditions; directly comparable in pursuing novel immune-modulating approaches to ARDS.
  • BioLineRx: Clinical-stage biopharmaceutical company developing immunomodulatory therapeutics; comparable small-cap clinical pipeline model focused on immune-related diseases.
  • RedHill Biopharma: Specialty biopharmaceutical company developing therapeutics for gastrointestinal and inflammatory diseases; similar clinical-to-commercial-stage profile and immunology focus.

Emerging players

  • Pluristem Therapeutics: Clinical-stage cell therapy company developing PLX cells for inflammatory and pulmonary conditions including ARDS; overlapping host-directed therapeutic strategy.
  • Athersys: Clinical-stage cell therapy company that advanced MultiStem for ARDS; directly comparable in pursuing novel modalities for respiratory inflammation, though now restructured.
  • Compass Pathways: Clinical-stage biotechnology company developing novel therapies; comparable small-cap clinical-stage biotech with platform-based therapeutic approach, though focused on different therapeutic area.

Broad incumbents

  • Incyte Corporation: Established biopharmaceutical company with Opzelura (ruxolitinib cream), an approved treatment for vitiligo; directly competitive in EB06's target indication and a benchmark for vitiligo commercial opportunity.
  • Pfizer: Large pharmaceutical company with established immunology and dermatology franchises (e.g., JAK inhibitor programs for vitiligo); broad incumbent with overlapping indications and far greater commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Edesa Biotech social profiles

Digital presence

Edesa Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Edesa Biotech leadership team

Management profile

Number of profiles

Profiles5 records

Edesa Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Edesa Biotech funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Edesa Biotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edesa Biotech

What does Edesa Biotech do?

Edesa Biotech is a clinical-stage biopharmaceutical company developing first-in-class host-directed therapeutics—monoclonal antibodies and topical enzyme inhibitors—for inflammatory and immune-related diseases. The company is advancing three drug candidates: paridiprubart (EB05), an anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS); EB06, an anti-CXCL10 monoclonal antibody for moderate-to-severe vitiligo; and EB01, a topical sPLA2 inhibitor cream for allergic contact dermatitis.

Is Edesa Biotech a public or private company?

Edesa Biotech is a public company. It is classified as public and is currently operating.

When was Edesa Biotech founded?

Edesa Biotech was founded in 2015. It employs 11 to 50 people.

Where is Edesa Biotech based?

Edesa Biotech is headquartered in Markham, Canada, in the North America region.

How does Edesa Biotech make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Edesa Biotech's main competitors?

Direct peers on record are Faron Pharmaceuticals, InMed Pharmaceuticals, Mesoblast, BioLineRx and RedHill Biopharma. Emerging players are Pluristem Therapeutics, Athersys and Compass Pathways. Broad incumbents are Incyte Corporation and Pfizer.

Does Edesa Biotech have an API?

No public API is recorded for Edesa Biotech.

What industry is Edesa Biotech in?

Edesa Biotech's product category is Clinical-stage Biopharmaceuticals / Host-Directed Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingEdesa Biotech's Paridiprubart Gains EU Orphan Drug Designation for ARDSEdesa Biotech announced Nov. 17, 2026, that paridiprubart received European Commission orphan designation for acute respiratory distress syndrome. Existing Phase 2/3 results showed improved survival among critically ill patients requiring invasive mechanical ventilation. The designation provides reduced development fees and potential market exclusivity following approval.TradingViewEdesa Biotech, Inc. (EDSA) Gets EU Orphan Designation for ARDS DrugThe European Commission granted orphan designation to Edesa Biotech's investigational paridiprubart for ARDS, supported by Phase 2/3 data showing statistically significant survival improvements. The designation provides regulatory incentives, including potential 10-year market exclusivity after approval, but no effect size was disclosed.Business & FinancialBiotech Stock Edesa Biotech, Inc. (Nasdaq: EDSA) Surges On Japanese DealEdesa Biotech's stock surged 44.39% to $3.09 after announcing an exclusive license deal with Kyorin Pharmaceutical for paridiprubart in Japan. The deal includes a $12 million upfront payment and milestones up to $134 million, with Kyorin funding development and commercialization for ARDS.FierceBiotechKyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drugKyorin Pharmaceutical agreed to pay $12 million upfront for Japan rights to Edesa Biotech's paridiprubart, an anti-TLR4 antibody for ARDS. Kyorin pledged up to $134 million in milestones and royalties, and will fund development and commercialization in Japan. The drug showed survival benefits in a phase 3 study, but Edesa halted the trial and shifted focus to general ARDS.Business & FinancialBiotech Stock Edesa Biotech (Nasdaq:EDSA) Gains On News Of Additional Positive Results From Phase 3 Paridiprubart StudyEdesa Biotech announced positive additional data from a Phase 3 study of paridiprubart, showing a 27% relative reduction in 28-day mortality across 278 patients. The drug reduced mortality from 33% to 24% in the full population, and from 23% to 15% in a milder group. The company filed provisional patent applications for sepsis, acute kidney injury, and pneumonia.TradingViewEdesa Biotech raises salaries of CEO Pardeep Nijhawan, President Michael Brooks and CFO Peter WeilerEdesa Biotech increased the annual base salaries of CEO Pardeep Nijhawan, President Michael Brooks, and CFO Peter Weiler, retroactive to July 1, 2026. Nijhawan's salary rose from $357,696 to $657,423, Brooks from $335,340 to $591,681, and Weiler from $300,000 to $525,938.Markets DailyEdesa Biotech (NASDAQ:EDSA) Cut to Strong Sell at Wall Street ZenWall Street Zen downgraded Edesa Biotech to a strong sell rating. The stock opened at $2.78, with an average analyst rating of Moderate Buy and a consensus price target of $5.00. The company reported a loss of $0.60 per share for the quarter, missing the consensus estimate.American Banking and Market NewsEdesa Biotech (NASDAQ:EDSA) Stock Dropped to Strong Sell by Wall Street ZenWall Street Zen downgraded Edesa Biotech to a strong sell, while Brookline Capital upgraded to strong buy. The company missed Q2 EPS estimates at -$0.60 versus -$0.44 expected, and Perceptive Advisors acquired a new stake. Analysts forecast a -1.99 EPS for the fiscal year.EIN PresswireEB06 Phase 2 Vitiligo Study Receives FDA IND Clearance | Dermatology TimesEdesa Biotech received FDA IND clearance for its phase 2 study of EB06, a fully human monoclonal antibody targeting CXCL10, in adults with moderate-to-severe nonsegmental vitiligo. The study's primary endpoint is the mean percent change in F-VASI at week 28, with topline data expected in Q4 2027. Enrollment in the US is planned to begin next quarter.MarketScreenerEdesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In VitiligoEdesa Biotech received FDA IND clearance for its Phase 2 study of EB06 in vitiligo, enabling U.S. recruitment. The double-blind, placebo-controlled trial evaluates the CXCL10-targeting antibody in up to 80 adults, with topline data expected in Q4 2027.